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ABSTRACT 
The cardiovascular and endocrine activity of three analogs of 
thyrotropin releasing hor.mone (TRH), 4-nitro-imidazole TRH (4-nitro-
TRH), 2-trifluoro-methyl-imidazole TRH (2-TFM-TRH) and 4-trifluoro-
methyl-imidazole TRH (4-TFM-TRH), was compared to TRH in conscious 
rats. Injection of TRH or the three analogs (1 mg/kg or 5 mg/kg) into 
the arterial line induced increases in mean arterial pressure, pulse 
pressure and heart rate and raised plasma prolactin (PRL). None of the 
analogs were more potent than TRH in inducing cardiovascular changes. 
The 4-TFM-TRH was significantly less potent than the 2-TFM-TRH in 
increasing blood pressure, while the nitro-TRH was more potent than the 
2-TFM-TRH in producing tachycardia. TRH induced a two-fold increase in 
PRL at the 5 mg/kg dose, while both the fluorinated analogs elici ted a 
4 to 5 fold increase in PRL at the higher dose. The present results 
suggest that the receptors for TRH-elicited PRL release differ from 
TRH-receptors involved in its cardiovascular actions. 
INTRODUCI'ION 
In addition to the thyrotropin release, thyrotropin releasing 
hor.mone (TRH) releases prolactin (PRL) from the pituitaLY of several 
mammalian species (1). Moreover, TRH has central nervous system 
actions which are totally unrelated to its effect on the hypothalamo-
pituitary axis (2,3). In both experimental animals (4-7) and humans 
(8,9), TRH producespresser and tachycardic responses. The variety of 
autonomic endocrine and neural functions regulated by TRH suggests that 
different receptors might mediate the various effects of TRH. The 
existance of multiple TRH receptors is supported by both biological 
(10,11) and biochemdcal studies (3,12,13). Appropriate modification of 
the TRH molecule might, therefore, yield analogs with an action 
selective for either neuroendocrine or central nervaus system. 
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Previous studies have shown that modification of the imddazole 
ring of histidine has profound effects on the biological activity of 
TRH. The N-methylated analog, 3-Me-Im-TRH, is about ten times as 
active as TRH in assays for TSH release while the l-me2hyl analog is 
inactive (14). Replacement of2histidine by [Pyr(l)Ala ) also gives an active analog while [Pyr(3)Ala] is only weakly active (15). Our pre-
vious studies have shown that 4-F-Im-TRH (4-Fluoro-TRH) and 2-TFM-TRH 
fail to bind to GH cells or release prolactin from them (16). On the 
other hand, discre~e central injection of these analogs to rats results 
in cardiovascular actions and PRL responses somewhat similar to those 
of TRH (17). In order to elaborate the effect of imidazole-ring Sub-
stitution in TRH on its biological profile, we have continued to 
synthetize and evaluate analogs in which the imidazole ring is modified 
by electron-releasing or electron-withdrawing groups in the 2- and;or 
4-position. As part of this study, we have prepar~ 2-trifluoro-
methyl-Im-TRH ( 2-TFM-TRH), 4-trifluoromethyl-Im-TRH ( 4-TFM-TRH) and 
4-nitro-Im-TRH (nitro-TRH) (18, Fig. 1) and report here the effects of 
these analogs on blood pressure, heart rate and plasma PRL levels in 
conscious rats. 
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Figure 1. Chemical structure of TRH, 2-TFM-TRH, 4-TFM-TRH and nitro-
TRH. 
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MATERIAL AND METII)DS 
Male Spraque-oawley rats (250-300 g) were purchased from Taconic 
Farms (Germantown, NY) and kept at 22°C and 12hr/12hr liqht/dark cycle. 
Polyethylene catheters (PE-50) were inserted into the femoral arteries 
under halothane (2\ in oxyqen) anesthesia. 'Ihe catheters were tunneled 
under the back skin and exteriorized at the nape of the neck. The 
lines were secured by a soft spring wire throughtout the cage as 
earlier described (19). Twenty-four hours after the surgery the 
arterial line was attached to a pressure transducer (Narco RP 1500i) 
and continuous recordings of blood pressure (systolic, diastolic, mean) 
and heart rate were carried out by the Narcotrace 80 computerized 
physioqraph. In addition, arterial blood sample (0.5 ml) was withdrawn 
before druq injection and at 5 and 30 min after the injection. Each 
blood sample withdrawn was replaced by an equal amount of fresh rat 
blood. This is a standard procedure in our conscious, chronically 
instrumented rats. 
Assay of plasma prolactin 
Plasma PRL levels were determined by radioimmunoassay using 
antibodies and standard { RP-2) supplied by the National Institute of 
Arthritis Metabolism and Digestive Diseases (20). This antibody was 
used in final assay dilution of 1:20 000. Iodinated PRL was obtained 
from New England Nuclear (Boston, MA;SA 20-5 Ci/,ug), and 10 000 
c~tube were used. Following a 24 hr incubation at 24°Ct bound 
material was separated using polyethylene glycol (21). The sensitivity 
of the assay is 2Spg;ml. 
Drugs used 
Thyrotropin releasing hormone (Sigma Chemical Co.) and the NO -, 
2-TFM- and 4-TFM analogs (Fig 1) were dissolved in saline {0.9\ Natl) 
and injected into the arterial line at the doses of 1mg/kg and 5mg/kg. 
Data in text and figures are mean±SDt for the indicated ntunber of 
rats. Analysis of variance followed by the Student-Newman-Keul test 
for multiple camparisans was used for statistical evaluation of the 
data. 
RESULTS 
Effect of the TRH analogs on bloodpressure and heart rate 
The effects of TRH and the three analogs on mean arterial pres-
sure, pulse pressure and heart rate are shown in Figure 2. Injection 
of TRH or the three analogs (1 or Smg/kg) into the arterial line 
increased the blood pressure and heart rate. The maximum increments of 
mean arterial pressure and heart rate were reached 5-15 min after each 
injection and the effect subsided in 30-45 minutes. None of the 
analogs tested were more potent than TRH in eliciting increases in mean 
arterial pressure, pulse pressure or heart rate. The 4-TFM-TRH was 
significantly less potent than the 2-TFM-TRH in increasing blood 
pressure, while the nitro-TRH was significantly more potent than the 
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2-TF.M-TRH in producing tachycardia. The increase in pulse pressure by 
the 4-TFM-TRH was also significantly lower than the effect induced by 
native TRH. 
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Fiqure 2. Maximum increases in mean acterial pressure, pulse pressure 
and heart rate following intra-arterial admdnistrations of saline T.RH, 
2-TFM-TRH, 4-TRM-TRH and nitro-TRH in the conscious rat. NUrober of 
rats in each group is given in parenthesis. Vertical bars indicate 
S.E.M. Asterisks and ''a" denote statistical significance by Student-
Newman-Keul test. 
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Effect on plasma prolactin 
The effect of TRH and the analogs on plasma PRL is demonstrated in 
the Figure 3. 'lbe higher dose of TRH ( Smg/kg) induced a twice-fold 
increase in plasma PRL. The maximum effect was achieved within 5 min 
after the injection and the levels were back to baseline values 30 min 
after the injection. Both the fluorinated analogs induced a 4-5 fold 
increment in plasma PRL at the Smg/kg dose, and the 2-TFM-TRH signifi-
cantly raised the PRL levels even at the lower dose. 'lhe ni tro-TRH 
elicited a sig.nificant decrease in the plasma PRL with the lmg/kg dose 
but had no effect at the higher dose. The effect of the nitro-TRH on 
PRL at the 1 mg/kg dose was signifcantly attenuated as compared to the 
increases in PRL induced by TRH, 2-TFM-TRH or 4-TFM-TRH. 
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Figure 3. Effects of TRH, 2-TFM-TRH, 4-TFM-TRH and nitro-TRH on plasma 
prolactin (PRL) level in the conscious rat. The two doses of each drug 
(lmg/kg and Smg/kg) were injected into the arterial line 120 min apart 
from each other. aaseline level of PRL is denoted by "B", 5 and 30 
indicates the appropriate time points after the drug administrations. 
Numbeer of rats in each group is given in parenthesis. vertical bars 
indicate S.E.M. Asterisks denote statistical significance from base-
line levels by Student-Newman-Keul test. The difference in baseline 
levels of PRL between the groups was not statistically significant. 
The increase in PRL induced by the nitro-TRH 5 min after the lmg/kg 
dose was dignificantly attenuated as compared to the increment of PRL 
produced by TRH, 2-TFM-TRH or 4-TRM-TRH (0<0.01). 
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DISCUSSION 
The present results confir.m the previous findings that TRH and its 
imidazole substituted analogs induce increments of blood pressure and 
heart rateandrelease prolactin (17). All the three analogs used in 
the present study were equipotent to TRH in eliciting cardiovascular 
changes. On the other hand, the 4-nitro-TRH was far less potent than 
the native TRH in inducing prolactin release, while the 2-TFM-TRH and 
4-TFM-TRH-analogs were significantly more potent than TRH in increasing 
plasma PRL. In a previous study (17) it has been reported that TRH and 
its 4-fluoro analog produced increases in blood pressure and heart rate 
and released prolactin also upon microinjections of nanomoles (28 
nmol•lO ~g) of these drugs into the hypothalamic nucleus preopticus 
medialis (POM). The 2-TFM-TRH was significantly less potent than TRH 
or the 4-fluoro-TRH in inducing tachycardia, while we did not find any 
significant differences between the cardiovascular effects of TRH and 
the 2-TFM-TRH. The difference in the raute of administration might 
explain this difference, i.e., systemic admdnistration of the compound 
might gain access to multiple brain sites in which cardiovascular 
responses can be elicited. The cardiovascular effects of TRH in the 
conscious rat are, however, similar both upon POM (6), intracerebroven-
tricular (22) and systemic administrations (23). 
The biological effects of 4-nitro-TRH and of 4-TFM-TRH have not 
been described previously. Although both analogs bear strong electro-
negative substituents at C-4 of the imidazole ring, their biological 
profiles are quite different. While they are equipotent with TRH in 
inducing cardiovascular changes, their effects on plasma PRL release 
stand in marked contrast. 4-Nitro-TRH is almost devoid of PRL activity 
while 4-TFM-TRH is significantly more active than TRH. These data 
therefore strongly suggest that the TRH receptors which mediate PRL 
release are different from the receptors involved in the cardiovascular 
effects of TRH. This selectivity might be due to the difference in 
Substitutions in the imidazole ring of TRH analogs. The nitro group is 
not only more electronegative than trifluoromethyl group but is much 
more capable of participating in intramolecular (or intennolecular) 
hydrogen bonds. Either or both of these effects may be directly 
responsible for selective binding to different TRH receptors, or 
indirectly responsible by creating different conformations of the 
peptide. Indeed, high resolution proton NMR spectroscopy does suggest 
conformational differences in the analogs by virtue of differences in 
coupling constant between the a-CH and ß-CH groups of histidine. 
oetailed NMR analysis of backhone and side ~hain conformations of these 
peptides is under investigation. 
It is now evident, therefore, that differentiation in the biologi-
cal activities of TRH can be achieved by selective Substitution in the 
imidazole ring of histidine. Thus, trifluoromethylated analogs of TRH 
may prove preferable to TRH in clinical assays based on prolactin 
release, while 4-nitro-TRH may be useful in clarifying the role of TRH 
in regulation of the cardiovascular system or in the treatment of shock 
states. 
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